• When it comes to drugs and TV ads, there is reason for skepticism: study

    About 73 percent of the drugs advertised on television have "low therapeutic value" as compared with existing, efficacious medications, according to a study published Jan. 13 in JAMA Open Network.
  • Florida warns pharmacies against distributing abortion pills

    The Florida Agency for Healthcare Administration warned pharmacies not to dispense abortion pills in light of the FDA's approval for pharmacies to do so in states where it is allowed, the Union-Bulletin reported Jan. 15.
  • Georgia hospital opens pharmacy

    Brunswick, Ga.-based Coastal Community Health opened its pharmacy after a year of expansions, The Brunswick News reported Jan. 16. 
  • Bivalent boosters not linked to stroke risk, federal agencies say

    Pfizer's updated COVID-19 booster does not increase the risk for ischemic stroke in patients 65 and older, according to a CDC and FDA review of multiple studies, reporting databases and other countries. 
  • 6 drugmakers are short on heparin

    Six drugmakers are reporting shortages of heparin, a blood thinner, and 19 solutions are back ordered for weeks, according to the American Society of Health-System Pharmacists. 
  • Walmart opens HIV-focused specialty pharmacy in New Jersey

    Walmart opened an HIV-focused specialty pharmacy in Hudson County, N.J., News12 New Jersey reported Jan. 14.
  • Paxlovid underprescribed for older adults, physician survey finds

    Physicians are hesitant to prescribe Paxlovid, a COVID-19 antiviral, to patients 65 and older mostly because of drug interaction worries, according to a survey conducted by Medscape. 
  • 21 flu drugs in shortage, most with no resupply date

    Eight drugmakers together have 21 oseltamivir presentations — a common flu drug sold under the brand name Tamiflu — on back order and allocation, and most cannot estimate a resupply date, according to the American Society of Health-System Pharmacists. 
  • 4 legislators prod J&J for answers over Tylenol, Motrin shortages

    As the shortage of children's pain medications continues, four Massachusetts lawmakers questioned Johnson & Johnson, the largest U.S. pharmaceutical company by revenue, about its supply of Tylenol and Motrin in a letter sent Jan. 12. 
  • FDA approves 1st combined asthma drug for adults

    The FDA approved Airsupra, the first asthma drug combination of an inhaled corticosteroid and a short-acting beta-agonist, Jan. 11. 
  • 2022 below annual average of novel drug approvals: 5 report notes

    The FDA approved 37 novel drugs in 2022 — the third lowest number since 2013 — according to a Jan. 10 agency report.  
  • Mark Cuban's pharmacy partners with 3rd PBM

    Mark Cuban Cost Plus Drugs Co. and pharmacy benefit manager RxPreferred Benefits partnered to bring Mr. Cuban's online pharmacy to employers and their members part of the PBM, the two companies said Jan. 11. 
  • Colorado considers capping cost of EpiPens

    Colorado lawmakers are floating a bill to cap the cost of epinephrine autoinjectors, commonly known as EpiPens, Colorado Public Radio reported Jan. 11. 
  • 10 systems seeking pharmacy leaders

    The following 10 hospitals, health systems and hospital operators have posted job listings seeking pharmacy leaders in the last week.
  • It's time to 'fully embrace' weight loss drugs, ECRI says

    After debunking common myths about weight loss drugs, the Emergency Care Research Institute, a patient safety nonprofit, said healthcare needs to "fully embrace" these FDA-approved medications. 
  • HHS decides on 3 Inflation Reduction Act deadlines

    HHS outlined three dates for the implementation of the Inflation Reduction Act, a sweeping drug pricing bill that President Joe Biden signed in 2022, CMS said Jan. 11. 
  • 4 pressing drug shortages

    As hospitals face dozens of drug supply issues, drug shortages have a semantics caveat, according to Erin Fox, PharmD. 
  • 'Unacceptable corporate greed': Senator slams Moderna for proposed vaccine cost

    Sen. Bernie Sanders sent a letter to Moderna's CEO urging the company to reconsider its price per dose in light of the federal government's role in developing the vaccine.
  • FDA takes wary approach on trials with cutting-edge drugs: WSJ

    The FDA is increasingly hesitant on allowing drugmakers to test their cell and gene therapy candidates in human trials, The Wall Street Journal reported Jan. 10. 
  • Nasal COVID-19 vaccines: 7 things to know

    With the COVID-19 public health emergency approaching an end date and some vaccine-makers prepping for their shots to plunge into the U.S. market, many anticipate nasal COVID-19 vaccines to join the fray. 

Featured Whitepapers

Featured Webinars